A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Acronyms COTEZO; IMblaze370
- Sponsors Roche
- 30 Oct 2022 Results of pooled analysis form NCT03178851, NCT01689519, NCT02322814, and NCT02788279 of safety analysis, published in the Drug Safety
- 03 Jul 2021 Results constructing hybrid control for the Morpheus metastatic colorectal cancer trial using IMblaze370 historical trial data presented at the 23rd World Congress on Gastrointestinal Cancer
- 04 Jul 2020 Results (n=296), of exploratory post-hoc biomarker analysis presented at the 22nd World Congress on Gastrointestinal Cancer